Stock AnalizLegend Biotech Corp LEGN
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Legend Biotech Corp (LEGN) is a healthcare company listed in the US with a market value of about $3.4B. In the twelve months to September 30, 2026 it had revenue of $1.4B and net income of -$200000, a net margin of -0.0%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 69% a year, a 5-year average ROIC of -28%.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.0B | $627M | $285M | $117M | $69M | $75M | $60M | $49M |
| Net income | -$200000 | -$297M | -$177M | -$518M | -$446M | -$404M | -$266M | -$102M | -$3M |
| Free cash flow | -$187M | -$129M | -$158M | -$413M | -$222M | -$241M | -$249M | -$110M | $287M |
| EPS (diluted) | $-0.00 | $-1.53 | $-0.91 | $-2.66 | $-2.29 | $-2.08 | $-1.37 | $-0.52 | $-0.01 |
| Net margin | -0.0% | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | -355.2% | -169.4% | -5.7% |
| ROIC | — | -8.2% | -18.2% | -34.3% | -35.0% | -45.5% | -44.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $42.54, 143% above the current price; targets range from $21.00 to $65.00; the consensus rating is “Buy”; expected EPS is $0.12 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Legend Biotech pay a dividend?
Not currently.
Is Legend Biotech a good stock to buy?
We do not give buy or sell advice. Legend Biotech scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.